US Recombinant Vaccines Market Research Report: By Product (Subunit Recombinant, Attenuated Recombinant Vaccines), By Disease (Cancer, Pneumococcal Disease, Hepatitis B, DPT) and By End-Users (Pediatrics, Adults, Veterinary) - Forecast to 2035

US Recombinant Vaccines Market Overview:

As per MRFR analysis, the US Recombinant Vaccines Market Size was estimated at 60.9 (USD Million) in 2023. The US Recombinant Vaccines Market Industry is expected to grow from 78.35(USD Million) in 2024 to 473.58 (USD Million) by 2035. The US Recombinant Vaccines Market CAGR (growth rate) is expected to be around 17.769% during the forecast period (2025 - 2035).

Key US Recombinant Vaccines Market Trends Highlighted

The US Recombinant Vaccines Market is experiencing significant growth driven by several key market drivers. The increasing incidence of infectious diseases, coupled with rising public awareness about preventive healthcare, has led to greater acceptance and demand for vaccines. Government initiatives, such as the National Vaccine Plan, aim to enhance vaccination rates and promote research and development in the recombinant vaccine space. Moreover, advancements in biotechnology and genetic engineering are allowing for the creation of more effective and safer vaccines, making these products more appealing to healthcare providers and patients alike.Opportunities within this market are expanding, particularly in the realm of vaccine development for emerging infectious diseases and potential bioterrorism threats. The US has seen a concentrated effort from both private and public sectors to develop vaccines that can respond promptly to outbreaks. There is also a growing trend towards personalized medicine, where vaccines can be tailored to individual genetic profiles, offering a more customized approach to immunization. Recent trends in the US include increased collaboration between biotech firms and governmental agencies for vaccine development. There has been a shift towards utilizing platforms that allow rapid response to vaccine production, such as mRNA technology, which gained traction during the COVID-19 pandemic.The focus on accessibility and equitable distribution of vaccines across various demographics in the US is also becoming a priority, driven by the recognition of health disparities. Overall, the US Recombinant Vaccines Market is evolving, influenced by these trends that emphasize innovation, collaboration, and public health priorities.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Recombinant Vaccines Market Drivers

Rising Demand for Preventive Healthcare

The US Recombinant Vaccines Market Industry is witnessing increased attention towards preventive healthcare due to the growing public awareness about vaccination benefits. According to the Centers for Disease Control and Prevention, vaccination rates in the United States have seen improvements with influenza vaccination coverage reaching approximately 50% of the population in recent years. This trend is significantly driven by the rise in communicable diseases and the desire to prevent outbreaks.Major organizations such as the American Academy of Pediatrics and the National Foundation for Infectious Diseases are actively promoting vaccination campaigns, which supports the market's growth as more individuals seek out recombinant vaccines that are safer and show fewer side effects compared to traditional vaccines.

Technological Advancements in Vaccine Development

Advancements in biotechnology and genetic engineering are pivotal in shaping the US Recombinant Vaccines Market Industry. The development of novel recombinant vaccine platforms has increased production efficiency and efficacy rates. The National Institutes of Health has reported a steady increase in Research and Development (R&D) funding for vaccine development, with federal funding exceeding $1 billion annually. Furthermore, improvements in production technologies have led to a significant reduction in the time and cost associated with bringing new vaccines to market, enabling rapid responses to health emergencies.As vaccines become faster and cheaper to produce, the market is poised for significant growth.

Increase in Infectious Disease Outbreaks

The resurgence of infectious diseases, such as measles and pertussis, triggering public health emergencies has heightened the need for effective vaccination solutions in the US Recombinant Vaccines Market Industry. The Centers for Disease Control and Prevention reported an alarming increase in measles cases, with over 1,200 cases reported in the US in 2019, the highest number since 1992. Such outbreaks underline the urgency for innovative vaccines that can mitigate these risks.This growing concern among health authorities and the public drives demand for recombinant vaccines, leading to investments and collaborations among pharmaceutical companies and public health agencies to develop effective vaccination strategies.

US Recombinant Vaccines Market Segment Insights:

Recombinant Vaccines Market Product Insights

The US Recombinant Vaccines Market reflects significant advancement in biotechnology, with a robust focus on the Product segment, which encompasses various innovative solutions such as Subunit Recombinant and Attenuated Recombinant Vaccines. Within this realm, Subunit Recombinant Vaccines stand out for their ability to provoke a strong immune response through the use of purified protein subunits, making them particularly suitable for addressing complex infectious diseases. This method minimizes the risk of adverse reactions commonly associated with traditional vaccines, thereby gaining preference among healthcare providers and patients alike.Meanwhile, Attenuated Recombinant Vaccines are noteworthy as they utilize live organisms that have been weakened to elicit immune responses without causing disease. This particular approach holds a significant share in the market due to its effectiveness in producing lasting immunity, thus appealing to various immunization programs aimed at eradicating diseases. The US government has been actively promoting the use of vaccines, responding to public health challenges by investing in Research and Development to enhance these products, aiming to ensure the population remains resilient against emerging pathogens.Market trends reveal a growing awareness among consumers regarding vaccine safety and efficacy, contributing to the uptick in demand for recombinant vaccines. Furthermore, ongoing collaborations among biopharmaceutical companies and academic institutions are driving innovation in this space, paving the way for the development of next-generation vaccines that address unmet medical needs. However, challenges remain, such as regulatory hurdles and public perception issues related to vaccines that require strategic engagement from stakeholders across the health sector.As the industry forges ahead, opportunities for growth exist via partnerships and investments in technology that can expedite vaccine development and improve distribution efficiency across the United States. These elements together create a dynamic landscape for the Product segment within the US Recombinant Vaccines Market, highlighting the importance of continuous evolution in response to both market demands and global health priorities.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Recombinant Vaccines Market Disease Insights

The Disease segment of the US Recombinant Vaccines Market remains a critical focus area, reflecting the ongoing need for effective immunization solutions against various health threats. Among the prominent categories within this segment, Cancer vaccines are gaining significant attention due to the rising incidence of cancer in the United States, making them crucial for preventive healthcare strategies. Meanwhile, Pneumococcal Disease vaccines hold a vital role in reducing morbidity and mortality associated with pneumonia, particularly in vulnerable populations such as children and the elderly.The Hepatitis B vaccine remains a cornerstone in the fight against viral hepatitis, which poses substantial public health challenges. Additionally, the DPT (Diphtheria, Pertussis, and Tetanus) vaccines continue to be essential for maintaining herd immunity and preventing outbreaks of these diseases. The US government’s initiatives toward vaccination drive and the constant advancements in recombinant technologies are further driving the growth and significance of these vaccines, reinforcing the importance of the Disease segment in public health.Capitalizing on these trends presents opportunities for innovation and improved health outcomes across the nation.

Recombinant Vaccines Market End-Users Insights

The US Recombinant Vaccines Market exhibits significant insights across its End-Users segment, primarily focusing on Pediatrics, Adults, and Veterinary applications. The Pediatrics segment plays a crucial role in safeguarding children from contagious diseases, as effective vaccination strategies continue to evolve through advancements in recombinant technology. Adults are also increasingly recognized as a vital demographic, particularly as vaccine recommendations expand to encompass various age groups and health concerns. This shift underscores a growing emphasis on preventative healthcare, driven by rising awareness and the need for immunizations in combating diseases.The Veterinary segment is gaining traction as health priorities shift towards animal welfare and public safety, especially in zoonotic disease prevention, which further integrates veterinary health into the broader healthcare landscape. Various factors, including increased government support and funding for vaccine development, align with the broader trend of prioritizing health security and disease management across these subcategories. Overall, the US Recombinant Vaccines Market shows promising opportunities for continued growth and innovation within these essential End-Users.

US Recombinant Vaccines Market Key Players and Competitive Insights:

The US Recombinant Vaccines Market is a rapidly evolving sector that leverages advanced biotechnology for the development of vaccines designed to trigger strong immune responses against various infectious diseases. As public health continues to pivot towards innovative strategies for disease prevention, the competitive landscape within this market is becoming increasingly complex. Companies operating in this space are focusing on research and development to create more effective vaccines with improved safety profiles and the capability to address emerging health threats. With advancements in recombinant DNA technology, key players are investing in partnerships and collaborations to enhance their product pipelines and gain a competitive edge.ViroClinics Xplore stands out in the US Recombinant Vaccines Market with its robust research foundations and a focus on developing customized vaccine solutions. The company has established a solid presence in the region, driven by its expertise in advanced biotechnology and vaccine research. ViroClinics Xplore is recognized for its strengths in innovative platform technologies, enabling efficient vaccine development processes against endemic and pandemic threats. The firm's commitment to quality and regulatory compliance positions it favorably in this competitive market, appealing to various stakeholders, including public health organizations and biopharmaceutical companies looking for reliable partners in vaccine development.Seqirus has made significant strides in the US Recombinant Vaccines Market, predominantly recognized for its comprehensive portfolio of influenza vaccines and other preventive solutions. The company's strengths lie in its strong market presence, innovative approaches to vaccine manufacturing, and a focus on providing high-quality immunization products. Seqirus is notable for its leadership in developing recombinant influenza vaccines that meet the demands of a diverse population. The firm has also pursued strategic mergers and acquisitions that bolster its capabilities and product offerings, enhancing its competitive position in the US. Its commitment to research and development, combined with a strategic approach to understanding market needs, empowers Seqirus to remain a key player in the recombinant vaccines landscape, catering to the public's health needs amid evolving challenges.

Key Companies in the US Recombinant Vaccines Market Include:

ViroClinics Xplore

Seqirus

GenView

Merck

GlaxoSmithKline

Inovio Pharmaceuticals

Regeneron Pharmaceuticals

Moderna

Pfizer

Astellas Pharma

Sanofi

Johnson and Johnson

Bavarian Nordic

Novavax

US Recombinant Vaccines Market Industry Developments

Recent developments in the US Recombinant Vaccines Market have highlighted significant activities among key players. In September 2023, Merck announced advancements in their recombinant vaccine pipelines aimed at enhancing global health responses, particularly in infectious disease management. Meanwhile, Moderna has reported substantial growth in their market valuation due to the successful launch of their new mRNA-based recombinant vaccines, contributing to their prominence in combating viral outbreaks. Pfizer continues to expand its recombinant vaccine portfolio with innovations focusing on personalized medicine, which has attracted considerable investments. Additionally, Inovio Pharmaceuticals has secured partnerships to further their Research and Development efforts in the recombinant domain, aiming to expedite vaccine availability. Notably, in October 2022, GlaxoSmithKline embarked on a strategic acquisition of a biotechnology firm, which strengthened their recombinant vaccine capabilities. This trend of mergers and acquisitions underscores the escalating competition and strategic collaborations within the market. The cumulative growth of companies like Johnson and Johnson and Bavarian Nordic also reflects the increasing investments and innovations tailored towards enhancing vaccine efficacy and distribution across the United States. Overall, these ongoing developments underscore a dynamic landscape in the US recombinant vaccines sector.

US Recombinant Vaccines Market Segmentation Insights

Recombinant Vaccines Market Product Outlook

Subunit Recombinant

Attenuated Recombinant Vaccines

Recombinant Vaccines Market Disease Outlook

Cancer

Pneumococcal Disease

Hepatitis B

DPT

Recombinant Vaccines Market End-Users Outlook

Pediatrics

Adults

Veterinary

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	60.9(USD Million)
MARKET SIZE 2024	78.35(USD Million)
MARKET SIZE 2035	473.58(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	17.769% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	ViroClinics Xplore, Seqirus, GenView, Merck, GlaxoSmithKline, Inovio Pharmaceuticals, Regeneron Pharmaceuticals, Moderna, Pfizer, Astellas Pharma, Sanofi, Johnson and Johnson, Bavarian Nordic, Novavax
SEGMENTS COVERED	Product, Disease, End-Users
KEY MARKET OPPORTUNITIES	Increasing infectious disease outbreaks, Growing investment in R&D, Expanding vaccination programs, Advances in biotechnology, Rising public health awareness
KEY MARKET DYNAMICS	Growing prevalence of diseases, Advancements in biotechnology, Increased government funding, Rising public awareness, Stringent regulatory frameworks
COUNTRIES COVERED	US